Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation

被引：30
|
作者：
Soni, Sandeep [1 ]
Skeens, Micah [1 ]
Termuhlen, Amanda M. [1 ]
Bajwa, Rajinder P. S. [1 ]
Gross, Thomas G. [1 ]
Pai, Vinita [1 ,2 ]
机构：
[1] Nationwide Childrens Hosp, Div Pediat Hematol Oncol & BMT, Columbus, OH 43205 USA
[2] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
来源：
PEDIATRIC BLOOD & CANCER | 2012年 / 59卷 / 04期
关键词：
BMT; busulfan; levetiracetam; seizures; HIGH-DOSE BUSULFAN; ACUTE-LEUKEMIA PATIENTS; MARROW TRANSPLANTATION; DRUG-INTERACTIONS; PHARMACOKINETICS; CYCLOPHOSPHAMIDE; LORAZEPAM;
D O I：
10.1002/pbc.24126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were compared to a historical, but similar cohort of 25 patients who had received fosphenytoin. Levetiracetam was well tolerated and was efficacious in preventing seizures. Cost of drug, administration, and monitoring were also similar among the two groups. Due to non-induction of the hepatic cytochrome P450 enzymes, levetiracetam may lead to better dose assurance of busulfan in targeted dose regimens for HSCT. Pediatr Blood Cancer 2012;59:762764. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码：762 / 764
页数：3
相关论文
共 50 条
  • [21] Busulfan in Hematopoietic Stem Cell Transplantation
    Ciurea, Stefan O.
    Andersson, Borje S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (05) : 523 - 536
  • [22] Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation
    H Takama
    H Tanaka
    D Nakashima
    R Ueda
    Y Takaue
    Bone Marrow Transplantation, 2006, 37 : 345 - 351
  • [23] The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
    C Nilsson
    J Aschan
    P Hentschke
    O Ringdén
    P Ljungman
    M Hassan
    Bone Marrow Transplantation, 2003, 31 : 429 - 435
  • [24] The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
    Nilsson, C
    Aschan, J
    Hentschke, P
    Ringdén, O
    Ljungman, P
    Hassan, M
    BONE MARROW TRANSPLANTATION, 2003, 31 (06) : 429 - 435
  • [25] Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation
    Takama, H
    Tanaka, H
    Nakashima, D
    Ueda, R
    Takaue, Y
    BONE MARROW TRANSPLANTATION, 2006, 37 (04) : 345 - 351
  • [26] RETROSPECTIVE COMPARISON OF PHENYTOIN AND LEVETIRACETAM AS SEIZURE PROPHYLAXIS WITH HIGH DOSE BUSULFAN DURING ALLOGENEIC STEM CELL TRANSPLANT
    Mathew, S.
    Harnicar, S.
    Adel, N.
    Papadopoulos, E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S353 - S353
  • [27] Busulfan monitoring in hematopoietic stem cell transplantation
    Queraltó, J
    Carrascosa, C
    Peña, C
    Turà, M
    Farré, R
    CLINICA CHIMICA ACTA, 2005, 355 : S423 - S424
  • [28] IV busulfan: Pharmacokinetics in children undergoing hematopoietic stem cell transplant.
    Finkelstein, Y
    Schechter, T
    Doyle, J
    Verjee, Z
    Koren, G
    Dupuis, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P70 - P70
  • [29] Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting
    Ruiz-Argueelles, Guillermo J.
    Gomez-Almaguer, David
    Steensma, David P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (09) : 941 - 941
  • [30] Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study
    Jansing, Thaksin
    Sanpakit, Kleebsabai
    Tharnpanich, Trai
    Jiranantakan, Thanjira
    Niphandwongkorn, Vachira
    Chindavijak, Busba
    Suansanae, Thanarat
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2021, 38 (04) : 346 - 357
12345